Last reviewed · How we verify

Berberine; Insulin

Guangdong Provincial People's Hospital · FDA-approved active Small molecule Quality 2/100

Berberine; Insulin is a Small molecule drug developed by Guangdong Provincial People's Hospital. It is currently FDA-approved. Also known as: No other name.

Berberine, marketed by Guangdong Provincial People's Hospital, is a drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and ongoing use. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameBerberine; Insulin
Also known asNo other name
SponsorGuangdong Provincial People's Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Berberine; Insulin

What is Berberine; Insulin?

Berberine; Insulin is a Small molecule drug developed by Guangdong Provincial People's Hospital.

Who makes Berberine; Insulin?

Berberine; Insulin is developed and marketed by Guangdong Provincial People's Hospital (see full Guangdong Provincial People's Hospital pipeline at /company/guangdong-provincial-people-s-hospital).

Is Berberine; Insulin also known as anything else?

Berberine; Insulin is also known as No other name.

What development phase is Berberine; Insulin in?

Berberine; Insulin is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing